glucagon-like-peptide-2 has been researched along with Depressive-Disorder--Treatment-Resistant* in 1 studies
1 other study(ies) available for glucagon-like-peptide-2 and Depressive-Disorder--Treatment-Resistant
Article | Year |
---|---|
Glucagon-like peptide-2 but not imipramine exhibits antidepressant-like effects in ACTH-treated mice.
We investigated the effectiveness of glucagon-like peptide-2 (GLP-2) against refractory depression in adrenocorticotropic hormone (ACTH)-treated mice as a model of tricyclic antidepressant (TCA)-resistant depression. Chronic ACTH treatment (0.45 mg/kg, s.c., 14 days) weakened the antidepressant-like effects of imipramine (20 mg/kg, i.p., 6 days) in the forced-swim test (FST). Conversely, GLP-2 (3 μg/mice, i.c.v., 6 days) induced antidepressant-like effects in the ACTH-treated mice in the FST. ACTH-treatment increased basal serum corticosterone levels, with an additional increase induced by the FST. Imipramine or GLP-2 had no effect on the basal corticosterone level, but GLP-2 attenuated the additional increase caused by the FST. Moreover, GLP-2 increased 5-HT levels, but not 5-HIAA. These results suggest that GLP-2 induced antidepressant-like effects under imipramine-resistant conditions through increase in 5-HT levels. Topics: Adrenocorticotropic Hormone; Animals; Antidepressive Agents, Tricyclic; Behavior, Animal; Depressive Disorder, Treatment-Resistant; Disease Models, Animal; Glucagon-Like Peptide 2; Hydroxyindoleacetic Acid; Imipramine; Male; Mice; Serotonin; Up-Regulation | 2013 |